Neuroscience
Trials for Alzheimer’s Drug Halted After Poor Results
By KATIE THOMAS
The New York Times
06 August 2012
- Alzheimer's Disease: Negative Bapineuzumab Findings In Phase Iii Trial
Critical reading for those interested in Alzheimer's clinical trials: first results from the BAP Phase III program. The link includes additional links to a New York Times article and a company press release. From FierceBiotech: UPDATED: Pfizer, J&J...
- Alzheimer's: Bapineuzumab And Solanezumab
Survey shows dim faith in Lilly, Pfizer Alzheimer's drugs Ransdell Pierson | Reuters The Chicago Tribune June 19, 2012 [snip] "Results from the survey of 146 investors were released late on Tuesday by Mark Schoenebaum, a pharmaceutical analyst for...
- Alzheimer Disease: Discussions About Bexarotene
Discussions about Targretin (bexarotene): From The Wall Street Journal: Alzheimer's Families Clamor for Drug By Shirley S. Wang 11 February 2012 Read the article From the In The Pipeline blog: Bexarotene for Alzheimer's 13 February 2012 Read the...
- Alzheimer's: The Current Pipeline
FierceBiotechResearch has an article which presents a very brief overview of the current Alzheimer's disease drug pipeline: It is available at the link below: Making sense of the Alzheimer's drug pipeline FierceBiotechResearch March 15, 2011 —...
- Alzheimer's Disease: Rethinking Things?
A very readable piece from Gina Kolata of the New York Times: Doubt on Tactic in Alzheimer’s Battle By GINA KOLATA The New York Times Published: August 18, 2010 "The failure of a promising Alzheimer’s drug highlights the gap between diagnosis and...
Neuroscience
Alzheimer's Disease: A Wrap for BAP
Trials for Alzheimer’s Drug Halted After Poor Results
By KATIE THOMAS
The New York Times
06 August 2012
Read full article
---
Corporate Press Release: Read the release
Commentary from the In The Pipeline blog: In The Pipeline
Commentary from Pharmalot: Pharmalot
- Alzheimer's Disease: Negative Bapineuzumab Findings In Phase Iii Trial
Critical reading for those interested in Alzheimer's clinical trials: first results from the BAP Phase III program. The link includes additional links to a New York Times article and a company press release. From FierceBiotech: UPDATED: Pfizer, J&J...
- Alzheimer's: Bapineuzumab And Solanezumab
Survey shows dim faith in Lilly, Pfizer Alzheimer's drugs Ransdell Pierson | Reuters The Chicago Tribune June 19, 2012 [snip] "Results from the survey of 146 investors were released late on Tuesday by Mark Schoenebaum, a pharmaceutical analyst for...
- Alzheimer Disease: Discussions About Bexarotene
Discussions about Targretin (bexarotene): From The Wall Street Journal: Alzheimer's Families Clamor for Drug By Shirley S. Wang 11 February 2012 Read the article From the In The Pipeline blog: Bexarotene for Alzheimer's 13 February 2012 Read the...
- Alzheimer's: The Current Pipeline
FierceBiotechResearch has an article which presents a very brief overview of the current Alzheimer's disease drug pipeline: It is available at the link below: Making sense of the Alzheimer's drug pipeline FierceBiotechResearch March 15, 2011 —...
- Alzheimer's Disease: Rethinking Things?
A very readable piece from Gina Kolata of the New York Times: Doubt on Tactic in Alzheimer’s Battle By GINA KOLATA The New York Times Published: August 18, 2010 "The failure of a promising Alzheimer’s drug highlights the gap between diagnosis and...